Quantcast

Latest Aratana Therapeutics Inc. Stories

2014-09-18 20:23:06

KANSAS CITY, Kan., Sept. 18, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced the full exercise of the underwriters' option to purchase 675,000 additional shares of common stock in connection with the company's previously announced public offering of 4,500,000 shares of common stock. All of the shares are being...

2014-09-17 08:31:10

KANSAS CITY, Kan., Sept. 17, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced the pricing of its public offering of 4,500,000 shares of its common stock at a price to the public of $9.25 per share. Aratana has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common...

2014-09-09 08:30:47

AT-003 Demonstrates Greater Pain Control Over Time Compared to Placebo in Client-Owned Dogs KANSAS CITY, Kan., Sept. 9, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension (AT-003) for managing post-operative pain in...

2014-09-05 08:23:54

KANSAS CITY, Kan., Sept. 5, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced that it will present at the Morgan Stanley Global Healthcare Conference, to be held September 8-10, 2014, at the Grand Hyatt in New York City. Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the...

2014-08-12 08:29:08

--Conference Call Today, August 12, 2014, 8:30 a.m. Eastern Time-- KANSAS CITY, Kan., Aug. 12, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its second quarter 2014 results. "We continue to advance our highly innovative pipeline," stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana...

2014-08-07 20:23:55

KANSAS CITY, Kan., Aug. 7, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it has appointed Irvine O. Hockaday, Jr. to its Board of Directors where he will also serve on the Nominating and Corporate Governance Committee. Mr. Hockaday brings extensive executive and board leadership...

2014-08-07 16:28:08

Conference Call and Webcast scheduled for Tuesday August 12, 2014, 8:30 a.m. ET KANSAS CITY, Kan., Aug. 7, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals will host a conference call and live audio webcast on Tuesday, August 12, 2014, at 8:30 a.m. ET, to discuss its financial results for the quarter ended June 30,...

2014-07-02 08:26:23

KANSAS CITY, Kan., July 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. (NASDAQ: ADXS) for the...

2014-06-23 16:25:15

KANSAS CITY, Kan., June 23, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors. Mr. Roche has extensive operational and product launch expertise working for leading pharmaceutical...

2014-06-19 16:26:30

KANSAS CITY, Kan., June 19, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will participate in two upcoming investor conferences. Aratana will provide an overview of its business during a live presentation at the JMP Securities Healthcare Conference and will be available to...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'